Mahsa Mahjani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Mahsa Mahjani has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
Alireza Jafari
Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
2 shared publicationsHassan Ahangar
Department of Cardiology, School of Medicine, Mousavi Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
2 shared publicationsSaeed Ghobadi
Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia
2 shared publicationsSepehr Gohari
Student Research Center, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2 shared publications- Sepehr Gohari
Student Research Center, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
2 shared publications Sheida Gohari
Department of Systems Science and Industrial Engineering, State University of New York at Binghamton, Binghamton, USA
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2025 (1) , 8209394
Androgen Receptor and Tumor‐Associated Neutrophil Expression Across Breast Cancer Subtypes: Associations With Clinicopathological Characteristics
Objectives: This study is aimed at evaluating androgen receptor (AR) and tumor‐associated neutrophil (TAN) expressions in different breast cancer subtypes and their relationship with tumor differentiation, stage, and other clinicopathological markers. Methods: A cross‐sectional study was conducted on 84 breast cancer patients at Stages I–IV. Tumor tissues were assessed using immunohistochemistry for ER, PR, HER2, AR, and Ki67, along with TAN evaluation using hematoxylin and eosin staining. Associations between AR, TAN, and other clinical variables were analyzed using chi‐square, t ‐tests, and logistic regression. Results: AR was expressed in 70.2% of tumors and was significantly associated with ER positivity (OR = 74.31, p < 0.001), PR positivity (OR = 6.8, p = 0.01), and better differentiation (OR = 0.1 for poorly differentiated tumors, p = 0.035). AR positivity was highest in Luminal A/B subtypes (82%) and lowest in triple‐negative breast cancer (TNBC) (20%; OR = 0.06, 95% CI: 0.01–0.3). In contrast, TAN positivity was observed in 45.6% of cases and was most frequent in TNBC (67%; OR = 3.7, 95% CI: 0.9–15.3) and poorly differentiated tumors (71.4%). TANs were inversely associated with PR positivity (OR = 0.21, p = 0.014) and showed a significant association with vascular invasion ( p = 0.047). No significant associations were found between AR or TAN expression and metastatic status or neural invasion. Conclusion: AR is a defining marker for HR‐positive breast cancers and may serve as an indicator of lower tumor grade and differentiation status. TANs, however, are linked to more aggressive phenotypes, especially in TNBC, suggesting a role in driving tumor progression. This highlights the potential for AR and TAN expression patterns to refine patient stratification across breast cancer subtypes.
- 1 January 2025
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2025 (1) , 8209394
Open AccessAndrogen Receptor and Tumor‐Associated Neutrophil Expression Across Breast Cancer Subtypes: Associations With Clinicopathological Characteristics
Objectives: This study is aimed at evaluating androgen receptor (AR) and tumor‐associated neutrophil (TAN) expressions in different breast cancer subtypes and their relationship with tumor differentiation, stage, and other clinicopathological markers. Methods: A cross‐sectional study was conducted on 84 breast cancer patients at Stages I–IV. Tumor tissues were assessed using immunohistochemistry for ER, PR, HER2, AR, and Ki67, along with TAN evaluation using hematoxylin and eosin staining. Associations between AR, TAN, and other clinical variables were analyzed using chi‐square, t ‐tests, and logistic regression. Results: AR was expressed in 70.2% of tumors and was significantly associated with ER positivity (OR = 74.31, p < 0.001), PR positivity (OR = 6.8, p = 0.01), and better differentiation (OR = 0.1 for poorly differentiated tumors, p = 0.035). AR positivity was highest in Luminal A/B subtypes (82%) and lowest in triple‐negative breast cancer (TNBC) (20%; OR = 0.06, 95% CI: 0.01–0.3). In contrast, TAN positivity was observed in 45.6% of cases and was most frequent in TNBC (67%; OR = 3.7, 95% CI: 0.9–15.3) and poorly differentiated tumors (71.4%). TANs were inversely associated with PR positivity (OR = 0.21, p = 0.014) and showed a significant association with vascular invasion ( p = 0.047). No significant associations were found between AR or TAN expression and metastatic status or neural invasion. Conclusion: AR is a defining marker for HR‐positive breast cancers and may serve as an indicator of lower tumor grade and differentiation status. TANs, however, are linked to more aggressive phenotypes, especially in TNBC, suggesting a role in driving tumor progression. This highlights the potential for AR and TAN expression patterns to refine patient stratification across breast cancer subtypes.
- Open Access
- 24 November 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-11
The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials
Background: The low-grade chronic inflammation in diabetes plays an important role in development of cardiovascular and renal complications. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recognized as protective agents for cardio-renal complications. Interleukin-6 (IL-6) is positively associated with the pathophysiology of metabolic-related pathologies. The aim of this meta-analysis is to investigate the effect of SGLT2 inhibitors on blood IL-6 concentration in randomized controlled trials (RCTs). Methods: Embase, PubMed, and Scopus were systematically searched up to 1st of November 2023. The eligible studies were RCTs with adult population that had provided blood IL-6 for both control and intervention groups. Cochrane risk-of-bias tool were for study quality assessment. Data were analyzed using random effect model via Stata statistical software. Results: Eighteen studies with a total of 5311 patients were included. Of which 3222 and 2052 patients were in intervention and control arm, respectively. Of the total population, 49.7% were men. The study durations ranged from 8 to 52 weeks. The pooled analysis showed a significant association between the use of SGLT2 inhibitors and lower IL-6 levels (standardized mean difference (SMD) = -1.04, Confidence Interval (CI): -1.48; -0.60, I2 = 96.93%). Dapagliflozin was observed to have a higher IL-6-lowering effect (SMD = -1.30, CI: -1.89; -0.71, I2 = 92.52) than empagliflozin or canagliflozin. Sub-group analysis of control groups (SMD = -0.58 (-1.01, -0.15) and -1.35 (-2.00, -0.70 for the placebo and active control sub-groups, respectively) and duration of interventions (SMD = -0.78 (-1.28, -0.28) and -1.20 (-1.86, -0.55) for study duration of ≤ 12 and > 12 weeks, respectively) did not change the results. Meta-regression analysis showed a significant correlation between the level of HbA1c and IL-6-lowering efficacy of SGLT2 inhibitors. Conclusion: IL-6 levels are significantly reduced with the use of SGLT2 inhibitors with HbA1c as the only marker influencing such reductions, and dapagliflozin had the highest potency. The anti-inflammatory effect of SGLT2 inhibitors supports their broader use to address diabetic complications related to inflammatory responses.
- 24 November 2023
- Published by Springer Nature in BMC Endocrine Disorders
- Vol. 23 (1) , 1-11
Open AccessThe effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: a systematic review and meta-analysis of randomized controlled trials
Background: The low-grade chronic inflammation in diabetes plays an important role in development of cardiovascular and renal complications. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are recognized as protective agents for cardio-renal complications. Interleukin-6 (IL-6) is positively associated with the pathophysiology of metabolic-related pathologies. The aim of this meta-analysis is to investigate the effect of SGLT2 inhibitors on blood IL-6 concentration in randomized controlled trials (RCTs). Methods: Embase, PubMed, and Scopus were systematically searched up to 1st of November 2023. The eligible studies were RCTs with adult population that had provided blood IL-6 for both control and intervention groups. Cochrane risk-of-bias tool were for study quality assessment. Data were analyzed using random effect model via Stata statistical software. Results: Eighteen studies with a total of 5311 patients were included. Of which 3222 and 2052 patients were in intervention and control arm, respectively. Of the total population, 49.7% were men. The study durations ranged from 8 to 52 weeks. The pooled analysis showed a significant association between the use of SGLT2 inhibitors and lower IL-6 levels (standardized mean difference (SMD) = -1.04, Confidence Interval (CI): -1.48; -0.60, I2 = 96.93%). Dapagliflozin was observed to have a higher IL-6-lowering effect (SMD = -1.30, CI: -1.89; -0.71, I2 = 92.52) than empagliflozin or canagliflozin. Sub-group analysis of control groups (SMD = -0.58 (-1.01, -0.15) and -1.35 (-2.00, -0.70 for the placebo and active control sub-groups, respectively) and duration of interventions (SMD = -0.78 (-1.28, -0.28) and -1.20 (-1.86, -0.55) for study duration of ≤ 12 and > 12 weeks, respectively) did not change the results. Meta-regression analysis showed a significant correlation between the level of HbA1c and IL-6-lowering efficacy of SGLT2 inhibitors. Conclusion: IL-6 levels are significantly reduced with the use of SGLT2 inhibitors with HbA1c as the only marker influencing such reductions, and dapagliflozin had the highest potency. The anti-inflammatory effect of SGLT2 inhibitors supports their broader use to address diabetic complications related to inflammatory responses.
- Open Access
- 28 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
The effect of dietary approaches to stop hypertension and ketogenic diets intervention on serum uric acid concentration: a systematic review and meta-analysis of randomized controlled trials
Hyperuricemia as a risk factor for metabolic diseases is proved to be profoundly modified by dietary approaches. This systematic review and meta-analysis of randomized control trials (RCT) was conducted to investigate the effect of two nutritional interventions; dietary approaches to stop hypertension (DASH) diet and ketogenic diet (KD) on serum uric acid (UA) concentrations. Our systematic search was for RCTs in which KD or DASH diet were assigned to adults for at least 2 weeks or more. Until March 2023 in Embase, Web of Science, PubMed, and Scopus databases, 10 eligible RCTs that intervened with DASH diet (n = 4) or KD (n = 6) and had provided laboratory data on serum UA were found. Summary effect was calculated by random-effects model. Results from the meta-analysis of the 4 DASH diet RCTs with a total of 590 participants revealed significant decrease in serum UA after at least 4 weeks of interventions (mean difference (MD) = ‒0.25; 95% CI ‒0.4 to ‒0.1 mg/dL;p < 0.01; I2 = 0%). The pooled meta-analysis of the 6 included RCTs of KD reporting data of 267 participants showed no significant changes in serum UA (MD = 0.26; 95% CI ‒0.47 to 0.98 mg/dL, I2 = 95.32%). However, a non-significant reduction of UA in the subgroup analysis of very low-calorie KD (VLCKD) studies (MD = ‒0.04; 95% CI ‒0.29 to 0.22, I2 = 0%) was obtained. DASH diet has an ameliorating effect on serum UA and may be recommended for hyperuricemia states such as gout. In addition, we have shown that serum UA level following KD remained unchanged. Although, in view of the heterogeneity across the studies, further investigations are needed to determine the effect of KD and VLKD on serum UA concentrations.
- 28 June 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-10
Open AccessThe effect of dietary approaches to stop hypertension and ketogenic diets intervention on serum uric acid concentration: a systematic review and meta-analysis of randomized controlled trials
Hyperuricemia as a risk factor for metabolic diseases is proved to be profoundly modified by dietary approaches. This systematic review and meta-analysis of randomized control trials (RCT) was conducted to investigate the effect of two nutritional interventions; dietary approaches to stop hypertension (DASH) diet and ketogenic diet (KD) on serum uric acid (UA) concentrations. Our systematic search was for RCTs in which KD or DASH diet were assigned to adults for at least 2 weeks or more. Until March 2023 in Embase, Web of Science, PubMed, and Scopus databases, 10 eligible RCTs that intervened with DASH diet (n = 4) or KD (n = 6) and had provided laboratory data on serum UA were found. Summary effect was calculated by random-effects model. Results from the meta-analysis of the 4 DASH diet RCTs with a total of 590 participants revealed significant decrease in serum UA after at least 4 weeks of interventions (mean difference (MD) = ‒0.25; 95% CI ‒0.4 to ‒0.1 mg/dL;p < 0.01; I2 = 0%). The pooled meta-analysis of the 6 included RCTs of KD reporting data of 267 participants showed no significant changes in serum UA (MD = 0.26; 95% CI ‒0.47 to 0.98 mg/dL, I2 = 95.32%). However, a non-significant reduction of UA in the subgroup analysis of very low-calorie KD (VLCKD) studies (MD = ‒0.04; 95% CI ‒0.29 to 0.22, I2 = 0%) was obtained. DASH diet has an ameliorating effect on serum UA and may be recommended for hyperuricemia states such as gout. In addition, we have shown that serum UA level following KD remained unchanged. Although, in view of the heterogeneity across the studies, further investigations are needed to determine the effect of KD and VLKD on serum UA concentrations.
- Open Access
- 1 June 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (146) , 210-220
Assessment of Machine Learning Approaches to Predict in-Hospital Mortality in Patients Underwent Prosthetic Heart Valve Replacement Surgery
Background and Objective: Machine learning and artificial intelligence are useful tools to analyze data with multiple variables. It has been shown that the prediction models obtained by Machine learning have better performance than the conventional statistical methods. This study was aimed to assess the risk factors and determine the best machine ...
- 1 June 2023
- Published by Farname, Inc. in Journal of Advances in Medical and Biomedical Research
- Vol. 31 (146) , 210-220
Open AccessAssessment of Machine Learning Approaches to Predict in-Hospital Mortality in Patients Underwent Prosthetic Heart Valve Replacement Surgery
Background and Objective: Machine learning and artificial intelligence are useful tools to analyze data with multiple variables. It has been shown that the prediction models obtained by Machine learning have better performance than the conventional statistical methods. This study was aimed to assess the risk factors and determine the best machine ...